Table 1. Biological and clinical characteristics of hiMBL (n = 156) and Binet A CLL (n = 107) cohorts at diagnosis.
| Variable | hiMBL n (%) | CLL n (%) | P |
|---|---|---|---|
| Median follow-up, months (range) | 73 (1–307) | 95 (3–250) | 0.069 |
| Clinical variables at diagnosis | |||
| Age [years, median (range)] | 68 (30–89) | 63 (29–86) | 0.0002 |
| ≤60 | 25 (16) | 47 (44) | 6.9x10-7 |
| Sex | |||
| Male | 86 (55) | 66 (62) | 0.18 |
| WBC (mean ± SD; x109/L) | 11.8±2.5 | 22.2±13.1 | 1.5x10-12 |
| Absolute lymphocyte count (mean ± SD; x109/L) | 7.0±1.7 | 16.6±12.3 | 4.2x10-12 |
| CLL-type cells (mean ± SD; x109/L) | 3.1±1.2 | 12.0±11.1 | 1.4x10-12 |
| β2-microglobulin >3.5 mg/L* | 17 (11) | 12 (14) | 0.33 |
| Treated | 16 (10) | 44 (41) | 6.7x10-9 |
| Biological variables at diagnosis | |||
| IGHV homology [mean (25th-75th percentiles)] | 94.0 (91.6–96) | 96 (93–100) | 2.7x10-5 |
| IGHV unmutated (homology ≥98%)* | 28 (19) | 46 (44) | 1.5x10-5 |
| FISH* | |||
| Normal | 53 (40) | 41 (43) | 0.39 |
| del(11)(q22.3) | 2 (2) | 5 (5) | 0.12 |
| +12 | 19 (15) | 9 (9) | 0.18 |
| del(13)(q14) | 61 (47) | 43 (45) | 0.51 |
| del(17)(p13) | 0 (-) | 4 (4) | 0.031 |
* β2-microglobulin was available in 154 (99%) hiMBL and 87 (81%) Binet A CLL cases; IGHV status was available in 149 (96%) hiMBL and 105 (98%) Binet A CLL cases. FISH analyses were performed in 131 (84%) hiMBL and 95 (89%) Binet A CLL cases.